Merck & Co., Inc. (MRK)
| Market Cap | 329.85B |
| Revenue (ttm) | 61.40B |
| Net Income (ttm) | 2.31B |
| Shares Out | 2.53B |
| EPS (ttm) | 0.90 |
| PE Ratio | 144.70 |
| Forward PE | 14.46 |
| Dividend | $3.08 (2.37%) |
| Ex-Dividend Date | Mar 14, 2024 |
| Volume | 9,095,656 |
| Open | 128.94 |
| Previous Close | 129.55 |
| Day's Range | 128.94 - 130.50 |
| 52-Week Range | 99.14 - 133.10 |
| Beta | 0.40 |
| Analysts | Buy |
| Price Target | 131.15 (+0.71%) |
| Earnings Date | Apr 25, 2024 |
About MRK
Merck & Co., Inc. operates as a healthcare company worldwide. It operates through two segments, Pharmaceutical and Animal Health. The Pharmaceutical segment offers human health pharmaceutical products in the areas of oncology, hospital acute care, immunology, neuroscience, virology, cardiovascular, and diabetes under the Keytruda, Bridion, Adempas, Lagevrio, Belsomra, Simponi, and Januvia brands, as well as vaccine products consisting of preventive pediatric, adolescent, and adult vaccines under the Gardasil/Gardasil 9, ProQuad, M-M-R II, Variv... [Read more]
Financial Performance
In 2023, Merck & Co.'s revenue was $60.12 billion, an increase of 1.40% compared to the previous year's $59.28 billion. Earnings were $365.00 million, a decrease of -97.49%.
Financial StatementsAnalyst Forecast
According to 13 analysts, the average rating for MRK stock is "Buy." The 12-month stock price forecast is $131.15, which is an increase of 0.71% from the latest price.
News
Merck treatment for a type of uterus cancer fails trial
Merck said on Thursday its treatment for a type of uterus cancer did not meet the main goal of disease-free survival in a late-stage trial.
Merck Provides Update on Phase 3 KEYNOTE-B21 Trial Evaluating KEYTRUDA® (pembrolizumab) Plus Chemotherapy, With or Without Radiotherapy, for Patients With Newly Diagnosed, High-Risk Endometrial Cancer After Surgery With Curative Intent
RAHWAY, N.J.--(BUSINESS WIRE)---- $MRK #MRK--Merck Provides Update on Phase 3 KEYNOTE-B21 Trial.
Merck to Participate in the Bank of America Securities 2024 Healthcare Conference
RAHWAY, N.J.--(BUSINESS WIRE)---- $MRK #MRK--Merck to Participate in the Bank of America Securities 2024 Healthcare Conference.
Press Release Biocartis NV: Biocartis and Merck to Collaborate on Improving Patient Access to Personalized Medicine in Middle East and North Africa (MEA) Region
PRESS RELEASE - 06/05/2024, 07:00 CEST Biocartis and Merck to Collaborate on Improving Patient Access to Personalized Medicine in Middle East and North Africa (MEA) Region Biocartis (Mechelen, Belgium...
Merck Announces Phase 3 KEYNOTE-811 Trial Met Dual Primary Endpoint of Overall Survival (OS) as First-Line Treatment in Patients With HER2-Positive Advanced Gastric or Gastroesophageal Junction (GEJ) Adenocarcinoma
RAHWAY, N.J.--(BUSINESS WIRE)---- $MRK #MRK--Merck Announces KEYNOTE-811 Trial Met Dual Primary Endpoint as First-Line Treatment in Patients With HER2-Positive Advanced Gastric or GEJ Cancer.
Is Merck Stock Fully Valued At $130?
Merck (NYSE: MRK) recently reported its Q1 results, with revenues and earnings exceeding our estimates. The company garnered $15.8 billion in revenue and adjusted earnings of $2.07 per share, compared...
Merck Announces Positive Data for V116, an Investigational, 21-Valent Pneumococcal Conjugate Vaccine Specifically Designed for Adults
RAHWAY, N.J.--(BUSINESS WIRE)---- $MRK #MRK--Merck Announces Positive Data for V116, an Investigational, 21-Valent Pneumococcal Conjugate Vaccine Specifically Designed for Adults.
Merck's Cancer Drug and Vaccine Sales Drive Better-Than-Expected Results
Merck (MRK) shares advanced in intraday trading Thursday after the pharmaceutical firm reported better-than-expected quarterly results, and raised and narrowed its guidance on strong sales of its bloc...
Merck beats earnings expectations; raises outlook on strong Keytruda and vaccine sales
CNBC's Joe Kernen reports on the company's quarterly earnings results.
Merck raises 2024 profit forecast on strong cancer, HPV drugs sales
Merck & Co on Thursday raised its annual profit and revenue forecast on the back of strong sales for its blockbuster cancer drug Keytruda and human papillomavirus (HPV) vaccine Gardasil.
Merck beats earnings expectations, raises outlook on strong Keytruda and vaccine sales
The first-quarter results come as Merck shows substantial progress in preparing for Keytruda's patent expiration in 2028.
Merck's first-quarter results beat expectations amid healthy vaccine-sales growth
Merck & Co. Inc. on Thursday reported first-quarter results that beat analysts' expectations amid strong sales of vaccines and cancer drug Keytruda.
Merck Announces First-Quarter 2024 Financial Results
RAHWAY, N.J.--(BUSINESS WIRE)---- $MRK #MRK--Merck Announces First-Quarter 2024 Financial Results.
Higher Keytruda Sales To Drive Merck's Q1?
Merck (NYSE: MRK) will report its Q1 2024 results on Thursday, April 25. We expect the company to post revenue of $15.2 billion and adjusted earnings of $1.97, slightly ahead of the street estimates.
Cramer's week ahead: Earnings from Tesla, Merck and Big Tech
CNBC's Jim Cramer said next week's PCE index report will be the real gauge of inflation.
Merck Initiates Phase 3 Clinical Trial of MK-1084, an Investigational Oral KRAS G12C Inhibitor, in Combination with KEYTRUDA® (pembrolizumab) for First-Line Treatment of Certain Patients With Metastatic Non-Small Cell Lung Cancer
RAHWAY, N.J.--(BUSINESS WIRE)--Merck (NYSE: MRK), known as MSD outside of the United States and Canada, today announced it has initiated a Phase 3 clinical trial evaluating MK-1084, an investigational...
Big Pharma Stocks Need a Rethink. Investors Keep Making the Same Mistake.
Pfizer's patent expirations are great for humanity but terrible for investors. It's a common story across the drug industry.
Merck Foundation announced ‘‘Diabetes and Hypertension'' Media Recognition Awards 2024 for Asian Countries
MUMBAI, India--(BUSINESS WIRE)-- #Diabetes--Merck Foundation announced "Diabetes and Hypertension" Media Recognition Awards 2024 for Asian Countries.
Merck Foundation Announced "Diabetes and Hypertension" Media Recognition Awards 2024 for Latin American Countries
SAN JOSÉ, Costa Rica--(BUSINESS WIRE)-- #Diabetes--Merck Foundation announced "Diabetes and Hypertension" Media Recognition Awards 2024 for Latin American Countries.
REJOICE-Ovarian01 Phase 2/3 Trial of Raludotatug Deruxtecan Initiated in Patients with Platinum-Resistant Ovarian Cancer
BASKING RIDGE, N.J. & RAHWAY, N.J.--(BUSINESS WIRE)--REJOICE-Ovarian01 Phase 2/3 Trial of Raludotatug Deruxtecan Initiated in Patients with Platinum-Resistant Ovarian Cancer.
Merck's Corporate Venture M Ventures Arm Backs Nucleai to Advance Its First-in-class Spatial AI Biomarker in Active Clinical Enrollment
CHICAGO--(BUSINESS WIRE)--Nucleai, a spatial AI biomarker company that deciphers cellular conversations and maps cellular interactions within tissue samples to predict therapeutic outcomes, has secure...
Merck Continues the Fight against Schistosomiasis in a Storytelling Lab
ADDIS ABABA, Ethiopia--(BUSINESS WIRE)-- #BilharziaStorytellingLab--On March 22, 2024, Merck announced the winners of its third Bilharzia Storytelling Lab in Addis Ababa, Ethiopia.
After A 30% Fall In A Year Is Pfizer Stock A Better Pick Over Merck?
Given its attractive valuation, we believe Pfizer stock (NYSE: PFE) is a better pick than its peer — Merck stock (NYSE: MRK). MRK trades at a higher valuation multiple of 5.6x revenues vs.
Merck to Hold First-Quarter 2024 Sales and Earnings Conference Call April 25
RAHWAY, N.J.--(BUSINESS WIRE)---- $MRK #MRK--Merck to Hold First-Quarter 2024 Sales and Earnings Conference Call April 25.
Merck CEO on Winrevair Approval, Obesity Drug, Health Costs
Merck Chair and CEO Robert M. Davis discusses the US approval of Winrevair, a new treatment for a rare, dangerous form of high blood pressure.